PEPGEN INC. (PEPG) Current Ratio
- Current ratio · latest quarter: Value 13.36×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.36× | Current assets / current liabilities. $120.33M ÷ $9.01M ≈ 13.36× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 120.33M USD | Assets, Current |
| Current obligations | 9.01M USD | Liabilities, Current |
| Cash and equivalents | 22.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 94.47M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.09M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $120.33M | $9.01M | $22.76M | $94.47M | (m) | (m) | $1.09M | (m) | 13.36× |
| 2026-03-31 | $134.27M | $8.96M | $42.15M | $90.15M | (m) | (m) | $622.00K | (m) | 14.98× |
| 2025-12-31 | $150.96M | $12.65M | $60.51M | $87.94M | (m) | (m) | $822.00K | (m) | 11.94× |
| 2025-09-30 | $166.21M | $12.64M | $142.78M | $20.89M | (m) | (m) | $766.00K | (m) | 13.15× |
| 2025-06-30 | $77.49M | $16.36M | $35.07M | $39.58M | (m) | (m) | $856.00K | (m) | 4.74× |
| 2025-03-31 | $101.05M | $20.43M | $43.63M | $54.15M | (m) | (m) | $2.70M | (m) | 4.95× |
| 2024-12-31 | $123.76M | $16.70M | $49.42M | $70.77M | (m) | (m) | $1.75M | (m) | 7.41× |
| 2024-09-30 | $142.37M | $16.81M | $42.29M | $96.57M | (m) | (m) | $5.93M | (m) | 8.47× |
| 2024-06-30 | $164.78M | $22.11M | $66.08M | $95.22M | (m) | (m) | $7.74M | (m) | 7.45× |
| 2024-03-31 | $177.62M | $11.26M | $133.85M | $41.37M | (m) | (m) | $1.48M | (m) | 15.78× |
| 2023-12-31 | $112.68M | $17.53M | $80.77M | $29.63M | (m) | (m) | $1.00M | (m) | 6.43× |
| 2023-09-30 | $133.09M | $20.95M | $129.54M | (m) | (m) | (m) | $3.99M | (m) | 6.35× |
| 2023-06-30 | $150.38M | $16.94M | $147.03M | (m) | (m) | (m) | $1.81M | (m) | 8.88× |
| 2023-03-31 | $168.47M | $18.03M | $165.40M | (m) | (m) | (m) | $1.47M | (m) | 9.35× |
| 2022-12-31 | $186.08M | $18.83M | $181.75M | $0.00 | (m) | (m) | $1.36M | (m) | 9.88× |
| 2022-09-30 | $204.25M | $15.52M | $195.78M | (m) | (m) | (m) | $4.62M | (m) | 13.16× |
| 2022-06-30 | $226.48M | $20.58M | $218.82M | (m) | (m) | (m) | $5.39M | (m) | 11.01× |
| 2022-03-31 | $125.67M | $16.12M | $118.85M | (m) | (m) | (m) | $1.89M | (m) | 7.79× |
| 2021-12-31 | $139.99M | $10.32M | $132.90M | (m) | (m) | (m) | $3.24M | (m) | 13.56× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |